Atrogi gears up for next growth phase with new CEO at the helm
Privately held biotechnology company Atrogi develops first-in-class oral therapies...
Strong Phase Ib results elevate Camurus in the global GLP-1 race
In a market where GLP-1 drugs from Novo Nordisk...
Lytix Biopharma’s oncolytic immunotherapy ruxotemitide shows strong phase II data
Lytix Biopharma's partner Verrica Pharmaceuticals has presented new...
ScandiBio Therapeutics Enters Phase III With Mitochondrial-Focused Alzheimer's Treatment
With an unusually low profile, ScandiBio Therapeutics has...
Pfizer agrees with Metsera – wins bidding war with Novo Nordisk
Pfizer has entered into an agreement to acquire...
ESMO 2025: mRNA vaccine boosts checkpoint inhibitors
Patients with cancer who received mRNA-based COVID vaccines within...
Empros Pharma presents positive topline results for EMP16
Empros Pharma has reported positive topline results from the...
Thor Medical comments on the Telix agreement
Norwegian radiopharma pioneer Thor Medical has signed a...
Moberg Pharma comments on the license agreement with Karo Healthcare
Moberg Pharma has taken another step in...
Vesper Bio reports promising results in Phase Ib/IIa
Danish Vesper Bio has presented positive topline results from...
Sound Bioventures invests SEK 34 million in Boost Pharma
Danish cell therapy company Boost Pharma has secured 34...
Kimberly-Clark and Kenvue merge in multi-billion dollar deal
The American hygiene and consumer goods giant Kimberly-Clark has signed...
Investing in biotech – an article series
Senzime's Q3 sales up 52 per cent despite headwinds
Senzime delivers a strong Q3 report with revenue growth of...
Novo Nordisk challenges Pfizer in billion-dollar battle for Metsera
Novo Nordisk has made a bid worth...
Recipharm secures new multi-million grant from the Gates Foundation
Recipharm deepens its focus on next-generation vaccine manufacturing...
New license agreement complements strong quarter for Orion
Despite challenging comparative figures, Orion delivered a stable underlying...
New major investment will strengthen Europe's life science sector
Europe takes a new step to strengthen...
Xbrane on the FDA drama: "We are taking it seriously" while outlining the path forward
After the FDA's unexpected backlash for the biosimilar Ximluci,...
Science, Synergy & Strategy.
Health & Wealth episode #16: Cereno Scientific
With Sten R Sørensen, CEO and Rahul Agrawal, CMO and Head of R&D
Recipharm secures new multi-million grant from the Gates Foundation
Recipharm deepens its focus on next-generation vaccine manufacturing...
New license agreement complements strong quarter for Orion
Despite challenging comparative figures, Orion delivered a stable underlying...
New major investment will strengthen Europe's life science sector
Europe takes a new step to strengthen...
Xbrane on the FDA drama: "We are taking it seriously" while outlining the path forward
After the FDA's unexpected backlash for the biosimilar Ximluci,...
Drug development - how it works
Hemab Therapeutics raises USD 157 million in Series C
Danish-American Hemab Therapeutics recently closed a Series C round...
Strong growth and successful acquisitions drive MedCap
Life science company MedCap reports strong revenue growth during...
Nanoform enters strategic partnership with Revio Therapeutics
Nanoform and Revio Therapeutics have entered into a collaboration...
Privately held AAX Biotech gains global validation through Daiichi Sankyo agreement
The Solna-based biotech company AAX Biotech has initiated a...
XVIVO sets sights on 2026 after strengthening position in transplants
XVIVO reports a stable Q3 with stable profitability,...
Guard Therapeutics rages after missed targets
Guard Therapeutics presents topline results from the clinical phase...
SwedenBIO's CEO: How Sweden can strengthen its role in drug manufacturing and clinical trials
With a strong research base and globally recognized innovations...
Focused investments in the cards for Flerie
Life science investor Flerie reports a net asset value of 3...
Promising long-term data boosts Abera's nasal flu vaccine
Abera Bioscience has presented promising new long-term preclinical data...
Hologic to be taken private for up to $18,3 billion
Hologic has accepted an offer from Blackstone and...
Evaxion’s cancer vaccine shows lasting responses in phase II
Evaxion Biotech has presented promising two-year data from its...
Mass defections in Novo board after disagreement with major owner
Almost the entire board of Novo Nordisk resigns after...
VC DATABASE
COMPANY DATABASE
GRANT DATABASE
JOB DATABASE
Upcoming events
MedTech Summit 2026
A new, much-needed MedTech forum in one of Europe's leading life science clusters. As the first event of its kind...
Chronicles
AI braces for a crash – biotech waits for retail to return
The generalists about to jump on the bandwagon
Pfizer’s whining confirm it – Metsera is the perfect fit for Novo
All power to Sørensen – more turbulence ahead
